449 results on '"Jayne, David R W"'
Search Results
2. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial
3. The Glucocorticoid Toxicity Index-Metabolic Domains, an abridged version of the Glucocorticoid Toxicity Index: post-hoc analysis of data from the ADVOCATE trial
4. Glucocorticoid Toxicity Index scores by domain in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with avacopan versus standard prednisone taper: post-hoc analysis of data from the ADVOCATE trial
5. #2168 Lupus nephritis histopathological classification system: a questionnaire-based survey of the Renal Pathology Society (RPS)
6. #3140 Investigating the impact of Anti-IL5 therapy in eosinophilic granulomatosis with polyangiitis (EGPA): a three year longitudinal perspective
7. #386 Avacopan versus prednisone taper in newly diagnosed or relapsing granulomatosis with polyangiitis or microscopic polyangiitis in the ADVOCATE trial
8. #3076 A UK parallel cohort study on renal ANCA associated vasculitis outcomes for avacopan exposed and matched unexposed cohorts
9. #3108 Rituximab in adult-onset IgA vasculitis
10. #1356 Kidney phenotype in interstitial lung disease associated with ANCA-vasculitis: European Multicentre Study
11. #1355 Albuminuria after Induction Treatment and Kidney Prognosis in ANCA-associated Glomerulonephritis
12. #464 Survey results on the utility of the Renal Risk Score and Histopathological Classification of ANCA-glomerulonephritis
13. Long-term surveillance study of rituximab originator treated patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).
14. Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Results of an International Randomized Controlled Trial (PEXIVAS).
15. The plethora of immunomodulatory drugs: opportunities for immune-mediated kidney diseases
16. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial
17. Mepolizumab has clinical benefits including oral corticosteroid sparing irrespective of baseline EGPA characteristics.
18. Management of antineutrophil cytoplasmic antibody–associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations
19. Management of antineutrophil cytoplasmic antibody-associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations
20. Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan
21. Challenges of defining renal response in ANCA-associated vasculitis: call to action?
22. The composition and functional protein subsystems of the human nasal microbiome in granulomatosis with polyangiitis: a pilot study
23. Management of antineutrophil cytoplasmic antibody–associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations.
24. Challenges of defining renal response in ANCA-associated vasculitis: call to action?
25. Avacopan for ANCA-associated vasculitis – information for prescribers
26. Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS
27. Avacopan for ANCA-associated vasculitis – information for prescribers.
28. The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis
29. Hurdles to the introduction of new therapies for immune-mediated kidney diseases
30. Pooled Intravenous Immunoglobulin in the Management of Systemic Vasculitis
31. Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab and Remission Induction in ANCA-Associated Vasculitis
32. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection
33. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis
34. Opponentʼs comments
35. Con: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?
36. Renal function and ear, nose, throat involvement in anti-neutrophil cytoplasmic antibody-associated vasculitis: prospective data from the European Vasculitis Society clinical trials
37. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis
38. Avacopan for the Treatment of ANCA-Associated Vasculitis
39. COVID-19 and ANCA-associated vasculitis : recommendations for vaccine preparedness and the use of rituximab
40. The COVID-19 pandemic and ANCA-associated vasculitis - reports from the EUVAS meeting and EUVAS education forum
41. Slowly progressive anti-neutrophil cytoplasmic antibody-associated renal vasculitis: clinico-pathological characterization and outcome
42. Gusperimus: immunological mechanism and clinical applications
43. Impact of rituximab trials on the treatment of ANCA-associated vasculitis
44. Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis
45. Aggressive vasculitis after lung transplantation for cystic fibrosis
46. Eosinophilic granulomatosis with polyangiitis present and future
47. Introduction to the European Vasculitis Society 3rd International Vasculitis Course (Cambridge) case-based supplement
48. Refractory ANCA-associated vasculitis
49. A critical beat in eosinophilic granulomatosis with polyangiitis
50. Therapeutic dilemmas in relapsing renal ANCA-associated vasculitis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.